Nebenwirkungen · Abilify Maintena
Abilify Maintena 720 mg prolonged-release suspension for injection in pre-filled syringe Abilify Maintena 960 mg prolonged-release suspension for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 34
HOS-129468 · Präparat HOS-096717
Pregnancy, Drug withdrawal puerperium and syndrome neonatal perinatal conditions Reproductive Erectile dysfunction Galactorrhoea Priapism system and breast Gynaecomastia disorders Breast tenderness Vulvovaginal dryness General disorders Injection site paina Pyrexia Temperature regulation and administration Injection site induration Asthenia disorder site conditions Fatigue Gait disturbance (e.g. hypothermia, Chest discomfort pyrexia) Injection site reaction Chest pain Injection site erythema Peripheral oedema Injection site swelling Injection site discomfort Injection site pruritus Thirst Sluggishness Investigations Blood creatine Blood glucose Blood glucose phosphokinase increased fluctuation increased Blood glucose decreased Glycosylated haemoglobin increased Waist circumference increased Blood cholesterol decreased Blood triglycerides decreased
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-28T15:16:00Z · SHA-256 41ea025269b746fee63511b9edbf4ea222d53988b45b27fd317f27f82cafb4fe · Passage 7e8e8f0764286729d7419d02ba82a765a3e1f6bc95af3fa6059f48d2d92825c0 · Zeichen 10731–13041 im Abschnitt